135 related articles for article (PubMed ID: 10082170)
1. Pharmacokinetic properties of beta-lactamase inhibitors.
de la Pena A; Derendorf H
Int J Clin Pharmacol Ther; 1999 Feb; 37(2):63-75. PubMed ID: 10082170
[TBL] [Abstract][Full Text] [Related]
2. Comparative evaluation of the in vitro activity of three combinations of beta-lactams with beta-lactamase inhibitors: piperacillin/tazobactam, ticarcillin/clavulanic acid and ampicillin/sulbactam.
Sader HS; Tosin I; Sejas L; Miranda E
Braz J Infect Dis; 2000 Feb; 4(1):22-8. PubMed ID: 10788842
[TBL] [Abstract][Full Text] [Related]
3. beta-Lactamase activity in mycobacteria including Mycobacterium avium and suppression of their growth by a beta-lactamase-stable antibiotic.
Prabhakaran K; Harris EB; Randhawa B; Hastings RC
Microbios; 1995; 81(328):177-85. PubMed ID: 7752957
[TBL] [Abstract][Full Text] [Related]
4. [Stability of beta-lactamase inhibitors and beta-lactam antibiotics in parenteral formulations as well as in body fluids and tissue homogenates. Comparison of sulbactam, clavulanic acid, ampicillin and amoxicillin].
Wildfeuer A; Räder K
Arzneimittelforschung; 1991 Jan; 41(1):70-3. PubMed ID: 2049115
[TBL] [Abstract][Full Text] [Related]
5. Penicillins and beta-lactamase inhibitor combinations.
Mealey KL
J Am Vet Med Assoc; 2001 Jun; 218(12):1893-6. PubMed ID: 11417732
[TBL] [Abstract][Full Text] [Related]
6. Evolution of beta-lactamase inhibitors.
Jackson D
Pharmacotherapy; 1991; 11(2 ( Pt 2)):37S-39S. PubMed ID: 2041830
[TBL] [Abstract][Full Text] [Related]
7. Activities of various beta-lactams and beta-lactam/beta-lactamase inhibitor combinations against Acinetobacter baumannii and Acinetobacter DNA group 3 strains.
Brauers J; Frank U; Kresken M; Rodloff AC; Seifert H
Clin Microbiol Infect; 2005 Jan; 11(1):24-30. PubMed ID: 15649300
[TBL] [Abstract][Full Text] [Related]
8. Studies on the synergism of sulbactam and beta-lactam antibiotics under in vitro conditions and in healthy volunteers after intravenous administration. Antibacterial activity in vitro, compatibility and pharmacokinetics of the drugs in combination.
Wildfeuer A; Schmalreck A; Räder K; Eibel G; Pfaff G
Arzneimittelforschung; 1989 Jan; 39(1):94-100. PubMed ID: 2785802
[TBL] [Abstract][Full Text] [Related]
9. Detection of bacterial strains producing sulbactam- or tazobactam-sensitive beta-lactamases by the use of disks containing the inhibitors alone instead of combining them with antibiotics.
Banic S
APMIS; 2006 Jan; 114(1):3-9. PubMed ID: 16499654
[TBL] [Abstract][Full Text] [Related]
10. Overcoming resistance to beta-lactamase inhibitors: comparing sulbactam to novel inhibitors against clavulanate resistant SHV enzymes with substitutions at Ambler position 244.
Thomson JM; Distler AM; Bonomo RA
Biochemistry; 2007 Oct; 46(40):11361-8. PubMed ID: 17848099
[TBL] [Abstract][Full Text] [Related]
11. Comparative activities of the beta-lactamase inhibitors YTR 830, clavulanic acid and sulbactam combined with ampicillin and piperacillin against beta-lactamase producing anaerobic bacteria.
Nord CE
J Chemother; 1989 Jul; 1(4 Suppl):273-5. PubMed ID: 16312398
[No Abstract] [Full Text] [Related]
12. Following the reactions of mechanism-based inhibitors with beta-lactamase by Raman crystallography.
Helfand MS; Totir MA; Carey MP; Hujer AM; Bonomo RA; Carey PR
Biochemistry; 2003 Nov; 42(46):13386-92. PubMed ID: 14621983
[TBL] [Abstract][Full Text] [Related]
13. Novel imidazole substituted 6-methylidene-penems as broad-spectrum beta-lactamase inhibitors.
Venkatesan AM; Agarwal A; Abe T; Ushirogochi H; Yamamura I; Kumagai T; Petersen PJ; Weiss WJ; Lenoy E; Yang Y; Shlaes DM; Ryan JL; Mansour TS
Bioorg Med Chem; 2004 Nov; 12(22):5807-17. PubMed ID: 15498657
[TBL] [Abstract][Full Text] [Related]
14. Tazobactam forms a stoichiometric trans-enamine intermediate in the E166A variant of SHV-1 beta-lactamase: 1.63 A crystal structure.
Padayatti PS; Helfand MS; Totir MA; Carey MP; Hujer AM; Carey PR; Bonomo RA; van den Akker F
Biochemistry; 2004 Feb; 43(4):843-8. PubMed ID: 14744126
[TBL] [Abstract][Full Text] [Related]
15. [In vitro activity of beta-lactam agents and beta-lactamase inhibitors in clinical isolates of Acinetobacter baumannii].
López-Hernández S; Alarcón T; Delgado T; de Las Cuevas MC; López-Brea M
Rev Esp Quimioter; 1999 Jun; 12(2):140-3. PubMed ID: 10562675
[TBL] [Abstract][Full Text] [Related]
16. X-ray structure of the Asn276Asp variant of the Escherichia coli TEM-1 beta-lactamase: direct observation of electrostatic modulation in resistance to inactivation by clavulanic acid.
Swarén P; Golemi D; Cabantous S; Bulychev A; Maveyraud L; Mobashery S; Samama JP
Biochemistry; 1999 Jul; 38(30):9570-6. PubMed ID: 10423234
[TBL] [Abstract][Full Text] [Related]
17. The vitro efficacy of beta-lactam and beta-lactamase inhibitors against multidrug resistant clinical strains of Mycobacterium tuberculosis.
Dinçer I; Ergin A; Kocagöz T
Int J Antimicrob Agents; 2004 Apr; 23(4):408-11. PubMed ID: 15081094
[TBL] [Abstract][Full Text] [Related]
18. A randomized controlled clinical trial on piperacillin/tazobactam versus ticarcillin/clavulanic acid for the treatment of bacterial infections.
Hou F; Li J; Gao L; Chen Y
Chin Med J (Engl); 1998 Nov; 111(11):1039-43. PubMed ID: 11189212
[TBL] [Abstract][Full Text] [Related]
19. Overcoming enzymatic resistance in bacteria: impact on future therapy.
Labia R; Barthélémy M; Péduzzi J; Morand A; Tiwari K; Kazmierczak A
J Int Med Res; 1990; 18 Suppl 4():48D-57D. PubMed ID: 2282969
[TBL] [Abstract][Full Text] [Related]
20. Suppression of the growth of six potentially-pathogenic mycobacteria by beta-lactam/beta-lactamase-inhibitors.
Prabhakaran K; Harris EB; Randhawa B
Microbios; 1997; 91(366):7-14. PubMed ID: 9467917
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
